Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: Clues from a biomarker study

Francesco D. Tiziano, Rosa Lomastro, Lorena Di Pietro, Maria Barbara Pasanisi, Stefania Fiori, Carla Angelozzi, Emanuela Abiusi, Corrado Angelini, Gianni Sorarù, Alessandra Gaiani, Tiziana Mongini, Liliana Vercelli, Gessica Vasco, Giuseppe Vita, Gian Luca Vita, Sonia Messina, Luisa Politano, Luigia Passamano, Grazia Di Gregorio, Cristina MontomoliChiara Orsi, Angela Campanella, Renato Mantegazza, Lucia Morandi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognized (types I-III). All patients usually have 2-4 copies of a highly homologous gene (SMN2), which produces insufficient levels of functional survival motor neuron (SMN) protein due to the alternative splicing of exon 7. The availability of potential candidates to the treatment of SMA has raised a number of issues, including the availability of biomarkers. This study was aimed at evaluating whether the quantification of SMN2 products in peripheral blood is a suitable biomarker for SMA. Forty-five adult type III patients were evaluated by Manual Muscle Testing, North Star Ambulatory Assessment scale, 6-min walk test, myometry, forced vital capacity, and dual X-ray absorptiometry. Molecular assessments included SMN2 copy number, levels of full-length SMN2 (SMN2-fl) transcripts and those lacking exon 7 and SMN protein. Clinical outcome measures strongly correlated to each other. Lean body mass correlated inversely with years from diagnosis and with several aspects of motor performance. SMN2 copy number and SMN protein levels were not associated with motor performance or transcript levels. SMN2-fl levels correlated with motor performance in ambulant patients. Our results indicate that SMN2-fl levels correlate with motor performance only in patients preserving higher levels of motor function, whereas motor performance was strongly influenced by disease duration and lean body mass. If not taken into account, the confounding effect of disease duration may impair the identification of potential SMA biomarkers.

Original languageEnglish
Pages (from-to)630-636
Number of pages7
JournalEuropean Journal of Human Genetics
Volume21
Issue number6
DOIs
Publication statusPublished - Jun 1 2013

Fingerprint

Spinal Muscular Atrophies of Childhood
Spinal Muscular Atrophy
Motor Neurons
Cross-Sectional Studies
Biomarkers
Exons
Proteins
Vital Capacity
Photon Absorptiometry
Alternative Splicing
Genes
Outcome Assessment (Health Care)
Muscles
Mutation

Keywords

  • biomarker
  • outcome measure
  • real-time PCR
  • SMN
  • spinal muscular atrophy

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Medicine(all)

Cite this

Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients : Clues from a biomarker study. / Tiziano, Francesco D.; Lomastro, Rosa; Di Pietro, Lorena; Pasanisi, Maria Barbara; Fiori, Stefania; Angelozzi, Carla; Abiusi, Emanuela; Angelini, Corrado; Sorarù, Gianni; Gaiani, Alessandra; Mongini, Tiziana; Vercelli, Liliana; Vasco, Gessica; Vita, Giuseppe; Luca Vita, Gian; Messina, Sonia; Politano, Luisa; Passamano, Luigia; Di Gregorio, Grazia; Montomoli, Cristina; Orsi, Chiara; Campanella, Angela; Mantegazza, Renato; Morandi, Lucia.

In: European Journal of Human Genetics, Vol. 21, No. 6, 01.06.2013, p. 630-636.

Research output: Contribution to journalArticle

Tiziano, FD, Lomastro, R, Di Pietro, L, Pasanisi, MB, Fiori, S, Angelozzi, C, Abiusi, E, Angelini, C, Sorarù, G, Gaiani, A, Mongini, T, Vercelli, L, Vasco, G, Vita, G, Luca Vita, G, Messina, S, Politano, L, Passamano, L, Di Gregorio, G, Montomoli, C, Orsi, C, Campanella, A, Mantegazza, R & Morandi, L 2013, 'Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: Clues from a biomarker study', European Journal of Human Genetics, vol. 21, no. 6, pp. 630-636. https://doi.org/10.1038/ejhg.2012.233
Tiziano, Francesco D. ; Lomastro, Rosa ; Di Pietro, Lorena ; Pasanisi, Maria Barbara ; Fiori, Stefania ; Angelozzi, Carla ; Abiusi, Emanuela ; Angelini, Corrado ; Sorarù, Gianni ; Gaiani, Alessandra ; Mongini, Tiziana ; Vercelli, Liliana ; Vasco, Gessica ; Vita, Giuseppe ; Luca Vita, Gian ; Messina, Sonia ; Politano, Luisa ; Passamano, Luigia ; Di Gregorio, Grazia ; Montomoli, Cristina ; Orsi, Chiara ; Campanella, Angela ; Mantegazza, Renato ; Morandi, Lucia. / Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients : Clues from a biomarker study. In: European Journal of Human Genetics. 2013 ; Vol. 21, No. 6. pp. 630-636.
@article{0dbb6a27a926491aa1bc955fc2bf3bfd,
title = "Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: Clues from a biomarker study",
abstract = "Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognized (types I-III). All patients usually have 2-4 copies of a highly homologous gene (SMN2), which produces insufficient levels of functional survival motor neuron (SMN) protein due to the alternative splicing of exon 7. The availability of potential candidates to the treatment of SMA has raised a number of issues, including the availability of biomarkers. This study was aimed at evaluating whether the quantification of SMN2 products in peripheral blood is a suitable biomarker for SMA. Forty-five adult type III patients were evaluated by Manual Muscle Testing, North Star Ambulatory Assessment scale, 6-min walk test, myometry, forced vital capacity, and dual X-ray absorptiometry. Molecular assessments included SMN2 copy number, levels of full-length SMN2 (SMN2-fl) transcripts and those lacking exon 7 and SMN protein. Clinical outcome measures strongly correlated to each other. Lean body mass correlated inversely with years from diagnosis and with several aspects of motor performance. SMN2 copy number and SMN protein levels were not associated with motor performance or transcript levels. SMN2-fl levels correlated with motor performance in ambulant patients. Our results indicate that SMN2-fl levels correlate with motor performance only in patients preserving higher levels of motor function, whereas motor performance was strongly influenced by disease duration and lean body mass. If not taken into account, the confounding effect of disease duration may impair the identification of potential SMA biomarkers.",
keywords = "biomarker, outcome measure, real-time PCR, SMN, spinal muscular atrophy",
author = "Tiziano, {Francesco D.} and Rosa Lomastro and {Di Pietro}, Lorena and Pasanisi, {Maria Barbara} and Stefania Fiori and Carla Angelozzi and Emanuela Abiusi and Corrado Angelini and Gianni Sorar{\`u} and Alessandra Gaiani and Tiziana Mongini and Liliana Vercelli and Gessica Vasco and Giuseppe Vita and {Luca Vita}, Gian and Sonia Messina and Luisa Politano and Luigia Passamano and {Di Gregorio}, Grazia and Cristina Montomoli and Chiara Orsi and Angela Campanella and Renato Mantegazza and Lucia Morandi",
year = "2013",
month = "6",
day = "1",
doi = "10.1038/ejhg.2012.233",
language = "English",
volume = "21",
pages = "630--636",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients

T2 - Clues from a biomarker study

AU - Tiziano, Francesco D.

AU - Lomastro, Rosa

AU - Di Pietro, Lorena

AU - Pasanisi, Maria Barbara

AU - Fiori, Stefania

AU - Angelozzi, Carla

AU - Abiusi, Emanuela

AU - Angelini, Corrado

AU - Sorarù, Gianni

AU - Gaiani, Alessandra

AU - Mongini, Tiziana

AU - Vercelli, Liliana

AU - Vasco, Gessica

AU - Vita, Giuseppe

AU - Luca Vita, Gian

AU - Messina, Sonia

AU - Politano, Luisa

AU - Passamano, Luigia

AU - Di Gregorio, Grazia

AU - Montomoli, Cristina

AU - Orsi, Chiara

AU - Campanella, Angela

AU - Mantegazza, Renato

AU - Morandi, Lucia

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognized (types I-III). All patients usually have 2-4 copies of a highly homologous gene (SMN2), which produces insufficient levels of functional survival motor neuron (SMN) protein due to the alternative splicing of exon 7. The availability of potential candidates to the treatment of SMA has raised a number of issues, including the availability of biomarkers. This study was aimed at evaluating whether the quantification of SMN2 products in peripheral blood is a suitable biomarker for SMA. Forty-five adult type III patients were evaluated by Manual Muscle Testing, North Star Ambulatory Assessment scale, 6-min walk test, myometry, forced vital capacity, and dual X-ray absorptiometry. Molecular assessments included SMN2 copy number, levels of full-length SMN2 (SMN2-fl) transcripts and those lacking exon 7 and SMN protein. Clinical outcome measures strongly correlated to each other. Lean body mass correlated inversely with years from diagnosis and with several aspects of motor performance. SMN2 copy number and SMN protein levels were not associated with motor performance or transcript levels. SMN2-fl levels correlated with motor performance in ambulant patients. Our results indicate that SMN2-fl levels correlate with motor performance only in patients preserving higher levels of motor function, whereas motor performance was strongly influenced by disease duration and lean body mass. If not taken into account, the confounding effect of disease duration may impair the identification of potential SMA biomarkers.

AB - Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations of the SMN1 gene. Based on severity, three forms of SMA are recognized (types I-III). All patients usually have 2-4 copies of a highly homologous gene (SMN2), which produces insufficient levels of functional survival motor neuron (SMN) protein due to the alternative splicing of exon 7. The availability of potential candidates to the treatment of SMA has raised a number of issues, including the availability of biomarkers. This study was aimed at evaluating whether the quantification of SMN2 products in peripheral blood is a suitable biomarker for SMA. Forty-five adult type III patients were evaluated by Manual Muscle Testing, North Star Ambulatory Assessment scale, 6-min walk test, myometry, forced vital capacity, and dual X-ray absorptiometry. Molecular assessments included SMN2 copy number, levels of full-length SMN2 (SMN2-fl) transcripts and those lacking exon 7 and SMN protein. Clinical outcome measures strongly correlated to each other. Lean body mass correlated inversely with years from diagnosis and with several aspects of motor performance. SMN2 copy number and SMN protein levels were not associated with motor performance or transcript levels. SMN2-fl levels correlated with motor performance in ambulant patients. Our results indicate that SMN2-fl levels correlate with motor performance only in patients preserving higher levels of motor function, whereas motor performance was strongly influenced by disease duration and lean body mass. If not taken into account, the confounding effect of disease duration may impair the identification of potential SMA biomarkers.

KW - biomarker

KW - outcome measure

KW - real-time PCR

KW - SMN

KW - spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=84880961451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880961451&partnerID=8YFLogxK

U2 - 10.1038/ejhg.2012.233

DO - 10.1038/ejhg.2012.233

M3 - Article

C2 - 23073312

AN - SCOPUS:84880961451

VL - 21

SP - 630

EP - 636

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 6

ER -